Back to search

Article

Activated type 17 helper T cells affect tofacitinib treatment outcomes

2024-04-09

Abstract excerpt

<title>Abstract</title> <p><bold>Background</bold>: The incidence of ulcerative colitis (UC) is on the rise also in Japan. Simultaneously, therapeutic options, including biologics and Janus kinase (JAK) inhibitors, have significantly expanded over the past decade. Although tofacitinib (TOF), one of JAK inhibitors, is a viable option for patients with moderate to severe UC, there is insufficient data to predict re...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
a536a4f8-d626-50a7-a60c-2eefc6b8f94e
DOI
10.21203/rs.3.rs-4130967/v1
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Activated type 17 helper T cells affect tofacitinib treatment outcomesDOI 10.21203/rs.3.rs-4130967/v1
Select a neighboring publication to make it the new centre.